Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Onureg | azacitidine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | classical Hodgkin Lymphoma (cHL) after failure of ASCT | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic non small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Renal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : July 28, 2024